ESPN's inaugural esports competition for college students is premiering at Comicpalooza. Jamie McInall/Pexels

For the first time ever, ESPN is hosting the Collegiate Esports Championship, and it's chosen Houston's 11th annual Comicpalooza to host it on May 10 to May 12 at the George R. Brown Convention Center.

"We are honored ESPN has chosen Houston and Comicpalooza for their inaugural Collegiate Esports Championship," says Michael Heckman, Comicpalooza president and senior vice president at Houston First, in a release. "Each year we strive to provide unique experiences for our different pop culture fandoms. Esports is undoubtedly popular and expanding. Teaming up with ESPN to bring the CEC here allows us to engage our audiences in a completely new, exciting way."

Students from hundreds of schools have competed to make it to the semifinals and championship in Houston, and scholarships are on the line. The weekend will have 22 teams across five video games — Hearthstone, Heroes of the Storm, Overwatch, StarCraft II, and Street Fighter V — according to ESPN.

"As universities continue to grow their esports programs at the varsity, non-varsity and club levels, we're proud to be providing a platform for national exposure and recognition of some of the most talented players in the collegiate space," says John Lasker, vice president of Digital Media Programming for ESPN, in a release. "Through our collaboration with top publishers in the industry, players will be able to showcase their talent in high-level competition on some of the most prominent esports titles."

Attendees and fans have access to the events with a Comicpalooza pass, but can also opt for the conference's Gaming Speed Pass for extra perks like reserved seating, a private lounge, and opportunities to meet the talent. Conference goers can also compete themselves in several different video games, according to the website.

Houston is a growing hub for esports. Mainline, a spin off company of Houston-based sports marketing company FanReact, launched this year to account for the growing presence of esports. Mainline's CEO, Chris Buckner, tells InnovationMap in an interview earlier this year that, especially because of this ESPN competition, other cities have their eyes on Houston for esports.

"I have been personally in contact with every major university in the city and they all are taking esports seriously," Buckner says in an interview. "It's actually a really exciting time for esports in Houston."

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”

Chevron enters the lithium market with major Texas land acquisition

to market

Chevron U.S.A., a subsidiary of Houston-based energy company Chevron, has taken its first big step toward establishing a commercial-scale lithium business.

Chevron acquired leaseholds totaling about 125,000 acres in Northeast Texas and southwest Arkansas from TerraVolta Resources and East Texas Natural Resources. The acreage contains a high amount of lithium, which Chevron plans to extract from brines produced from the subsurface.

Lithium-ion batteries are used in an array of technologies, such as smartwatches, e-bikes, pacemakers, and batteries for electric vehicles, according to Chevron. The International Energy Agency estimates lithium demand could grow more than 400 percent by 2040.

“This acquisition represents a strategic investment to support energy manufacturing and expand U.S.-based critical mineral supplies,” Jeff Gustavson, president of Chevron New Energies, said in a news release. “Establishing domestic and resilient lithium supply chains is essential not only to maintaining U.S. energy leadership but also to meeting the growing demand from customers.”

Rania Yacoub, corporate business development manager at Chevron New Energies, said that amid heightening demand, lithium is “one of the world’s most sought-after natural resources.”

“Chevron is looking to help meet that demand and drive U.S. energy competitiveness by sourcing lithium domestically,” Yacoub said.

---

This article originally appeared on EnergyCapital.